within Pharmacolibrary.Drugs.ATC.S;

model S02AA01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.36166666666666664,
    adminDuration  = 600,
    adminMass      = 1.0,
    adminCount     = 1,
    Vd             = 0.0005600000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Chloramphenicol is a broad-spectrum antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. It is used to treat serious infections such as typhoid fever, meningitis, and eye infections, though its use has declined due to potentially severe side effects like aplastic anemia. It is still used in some countries, and topically for eye infections in others.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adults after intravenous administration.</p><h4>References</h4><ol><li><p>Nahata, MC, &amp; Powell, DA (1983). Comparative bioavailability and pharmacokinetics of chloramphenicol after intravenous chloramphenicol succinate in premature infants and older patients. <i>Developmental pharmacology and therapeutics</i> 6(1) 23–32. DOI:<a href=&quot;https://doi.org/10.1159/000457274&quot;>10.1159/000457274</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6839912/&quot;>https://pubmed.ncbi.nlm.nih.gov/6839912</a></p></li><li><p>Sullins, AK, &amp; Abdel-Rahman, SM (2013). Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. <i>Paediatric drugs</i> 15(2) 93–117. DOI:<a href=&quot;https://doi.org/10.1007/s40272-013-0017-5&quot;>10.1007/s40272-013-0017-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23529866/&quot;>https://pubmed.ncbi.nlm.nih.gov/23529866</a></p></li><li><p>Ambrose, PJ (1984). Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate. <i>Clinical pharmacokinetics</i> 9(3) 222–238. DOI:<a href=&quot;https://doi.org/10.2165/00003088-198409030-00004&quot;>10.2165/00003088-198409030-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6375931/&quot;>https://pubmed.ncbi.nlm.nih.gov/6375931</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end S02AA01;
